Stocks and Investing Stocks and Investing
Thu, July 20, 2017
Wed, July 19, 2017
Tue, July 18, 2017
Mon, July 17, 2017
Fri, July 14, 2017
Thu, July 13, 2017
Wed, July 12, 2017
Tue, July 11, 2017
Mon, July 10, 2017

Matthew Harrison Maintained (BIIB) at Hold with Decreased Target to $301 on, Jul 10th, 2017


Published on 2024-10-25 21:32:30 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $307 to $301 on, Jul 10th, 2017.

Matthew has made no other calls on BIIB in the last 4 months.



There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Upgraded from Strong Sell to Hold on, Monday, June 19th, 2017
  • Geoffrey Porges of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, March 16th, 2017


This is the rating of the analyst that currently disagrees with Matthew


  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy and Held Target at $315 on, Friday, June 23rd, 2017